Page 46

Notes REPORTS destructive enzymes: a potential thrapeutic role for tetracyclines and their chemfically-modified analogs. J. Periodontol. 64(suppl):819-827. 13. Kothari, M, and Simon, S.R. (2006) Chemically modified tetracyclines inhbit VEGF secretion by breast cancer cell lines. Cytokine 35:115-125. 14. Dinarello, CA (2006) Inhibitors of histone deacetylases as anti-inflammatory drugs. Ernst Schering Foundation Workshop 56:45-60. 15. Leoni, F. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 99:2995-3000. 16. Larsen, L. (2007) Inhibition of Histone deacetylases prevents cytokine induced toxicity in beta cells. Diabetologia. 50:779-789. 17. Garcia-Manerio, (2008) Phase 1 study of the histone deacetylase inhibitor varinostat in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060-1066. 18. Nandakumar, V., Singh, T, and Katiyar, SK (2008) Multi-targeted prevention and therapy of cancer by proanthocyanidins. Cancer Lett. 269:378-387. 19. Kocer, S.S., Walker, S.G., Zerler, B., Golub, L.M., and Simon, S.R. (2005) Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines and Ilomastat, block Bacillus anthracis lethal factor activity in viable cells. Infect. Immun. 73:7548-7557.

46

The Stony Brook Young Investigators Review, Fall 2011

Fall 2011

Profile for younginvestigators

Fall 2011  

Fall 2011  

Advertisement